Loading organizations...
§ Venture Capital · Paris, Ile-de-France, France
Global investment company financing and accelerating biopharma innovations for clinical-stage companies, focused on high unmet medical needs.
Jeito Capital has raised $76.0M across 1 funding round.
Key people at Jeito Capital.
Jeito Capital was founded in 2017 by Rafaèle Tordjman (Founder & CEO).
Jeito Capital has raised $76.0M in total across 1 funding round.
Jeito Capital, a global investment company based in Paris, France, was founded in 2018 by Dr. Rafaèle Tordjman, its President. With Managing Partners Sabine Dandiguian and Rachel Mears, the firm finances and accelerates biopharma innovations with a patient-driven approach. Jeito Capital manages over €1.6 billion in assets, through its Jeito I (€534 million) and Jeito II (over €1 billion) funds. It invests in clinical-stage companies, primarily in Europe and the US, focusing on high unmet medical needs such as oncology, autoimmune, and neurodegenerative conditions. A multidisciplinary team of over 30 experts provides guidance from clinical development to market access, fostering market leaders. Its business model centers on private equity and venture capital through dedicated funds like Jeito I and Jeito II, raising capital from institutional investors, family offices, and public investment banks to invest in biopharma companies.
Jeito Capital was founded in 2017 by Rafaèle Tordjman (Founder & CEO).
Jeito Capital has raised $76.0M in total across 1 funding round.
Jeito Capital's investors include Rafaèle Tordjman, Dan Marks, Claudio Nessi.
Key people at Jeito Capital.
Jeito Capital has raised $76.0M across 1 funding round. Most recently, it raised $76.0M Series A in April 2022.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Jan 7, 2025 | XyloCor Therapeutics | $67.5M Series B | Jeito Capital | — |
| Nov 12, 2024 | Alentis Therapeutics | $181.4M Series D | Jeito Capital, Novo Holdings, OrbiMed | — |
| Jan 1, 2024 | HI-Bio | $95.0M Bio - Series B | Chris Dimitropoulos | ARCH Venture Partners, Arkin BIO Ventures, Viking Global Investors |
| Nov 14, 2023 | Eyebiotech | $65.0M Series A Extension | Michael Ross, Andreas Wallnofer | Bain Capital Life Sciences, MRL Ventures Fund, Bernard Davitian, Samsara BioCapital, SV Health Investors, Christine Brennan |
| Apr 13, 2023 | Alentis Therapeutics | $105.0M Series C | Jeito Capital, Novo Holdings | — |
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Apr 13, 2022 | $76M Series A | Rafaèle Tordjman, DAN Marks | Claudio Nessi | Announced |
